Precigen
NASDAQ: PGENGermantown, US · Virginia corporation · 2 known investors
Precigen is a biopharmaceutical company developing gene and cell therapies, including PAPZIMEOS (zopapogene imadenovec-drba), an FDA-approved immunotherapy for adults with recurrent respiratory papillomatosis. The company focuses on immuno-oncology and immunotherapy treatments delivered via subcutaneous injection.
Founders & leadership
TD
Thomas D. ReedFounder
TR
Thomas R. KasserExecutive
SM
Suma M. KrishnanExecutive
DP
Donald P. LehrExecutive
RF
Robert F. Walsh, IIIExecutive
HS
Helen Sabzevari, PhDPresident and CEO
HS
Helen SabzevariinFounder
TK
Timothy KasbeNamed on SEC filing
JR
Jayson RiegerNamed on SEC filing
JK
Jeffrey KindlerNamed on SEC filing
DW
Darryl WebsterNamed on SEC filing
DL
Donald LehrNamed on SEC filing
Investors · 2
Reported raises · per SEC filings
Form D private placements$245.6M disclosed across 10 rounds · 2011–2020
▶$13MraisedDec 2020 · 2 investors · PharmaceuticalsRule 506(b)
▶$13MraisedDec 2020 · 2 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Rick L. SterlingExecutive Officer
- Donald P. LehrExecutive Officer
- Jeffrey PerezExecutive Officer
- Helen Sabzevari, Ph.D.Executive Officer, Director
- Randal J. KirkDirector
- Cesar L. AlvarezDirector
- James S. TurleyDirector
- Vinita D. GuptaDirector
- Fred HassanDirector
- Jeffrey B. KindlerDirector
- Dean J. MitchellDirector
- Robert B. ShapiroDirector
- Steven FrankDirector
- Offering amount
- $13M
- Amount sold
- $13M
- First sale
- Dec 2020
- Incorporated
- Corporation, Virginia
- Federal exemptions
- 06b
▶$35MraisedFeb 2020 · 1 investors · BiotechnologyRule 506(b)
▶$35MraisedFeb 2020 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- James S. TurleyDirector
- Robert B. ShapiroDirector
- Dean J. MitchellDirector
- Jeffrey B. KindlerDirector
- Fred HassanDirector
- Vinita D. GuptaDirector
- Steven FrankDirector
- Cesar L. AlvarezDirector
- Randal KirkDirector, Executive Officer
- Helen Sabzevari, Ph.D.Executive Officer
- Jeffrey PerezExecutive Officer
- Thomas Reed, Ph.D.Executive Officer
- Rick L. SterlingExecutive Officer
- Donald P. LehrExecutive Officer
- Offering amount
- $35M
- Amount sold
- $35M
- First sale
- Jan 2020
- Incorporated
- Corporation, Virginia
- Federal exemptions
- 06b
▶$4.3MraisedMar 2016 · 2 investors · BiotechnologyRule 506(b)
▶$4.3MraisedMar 2016 · 2 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- James S. TurleyDirector
- Samuel BroderExecutive Officer
- Jeffrey B. KindlerDirector
- Thomas D. ReedExecutive Officer
- Robert F. Walsh, IIIExecutive Officer
- Joseph L. VaillancourtExecutive Officer
- Rick L. SterlingExecutive Officer
- Cesar L. AlvarezDirector
- Steven FrankDirector
- Randal J. KirkExecutive Officer, Director
- Dean J. MitchellDirector
- Suma M. KrishnanExecutive Officer
- Ena Chan CratsenburgExecutive Officer
- Nir NimrodiExecutive Officer
- Joel D. LiffmannExecutive Officer
- Krish S. KrishnanExecutive Officer
- Robert B. ShapiroDirector
- Corey HuckExecutive Officer
- Jeffrey T. PerezExecutive Officer
- Donald P. LehrExecutive Officer
- Jack A. BoboExecutive Officer
- Offering amount
- $4.3M
- Amount sold
- $4.3M
- First sale
- Feb 2016
- Incorporated
- Corporation, Virginia
- Federal exemptions
- 06b
▶$21.6MraisedSep 2015 · 20 investors · BiotechnologyRule 506(b)
▶$21.6MraisedSep 2015 · 20 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Larry D. HornerDirector
- Dean J. MitchellDirector
- Olivier R. JarryExecutive Officer
- Donald P. LehrExecutive Officer
- Cesar L. AlvarezDirector
- Rick L. SterlingExecutive Officer
- Randal J. KirkExecutive Officer, Director
- James S. TurleyDirector
- Thomas D. ReedExecutive Officer
- Jeffrey T. PerezExecutive Officer
- Steven FrankDirector
- Krish S. KrishnanExecutive Officer
- Robert F. Walsh, IIIExecutive Officer
- Robert B. ShapiroDirector
- Joel D. LiffmanExecutive Officer
- Jeffrey L. KindlerDirector
- Jack A. BoboExecutive Officer
- Nir NimrodiExecutive Officer
- Suma M. KrishnanExecutive Officer
- Samuel BroderExecutive Officer
- Offering amount
- $21.6M
- Amount sold
- $21.6M
- First sale
- Sep 2015
- Incorporated
- Corporation, Virginia
- Federal exemptions
- 06b
▶$450KraisedMar 2015 · 1 investors · BiotechnologyRule 506(b)
▶$450KraisedMar 2015 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Krish S. KrishnanExecutive Officer
- Thomas R. KasserExecutive Officer
- Suma M. KrishnanExecutive Officer
- Donald P. LehrExecutive Officer
- Dean J. MitchellDirector
- Rick L. SterlingExecutive Officer
- Robert F. Walsh, IIIExecutive Officer
- Gregory I. FrostExecutive Officer
- James S. TurleyDirector
- Jeffrey T. PerezExecutive Officer
- Darryl WebsterExecutive Officer
- Thomas D. ReedExecutive Officer
- Steven FrankDirector
- Larry D. HornerDirector
- Randal J. KirkExecutive Officer, Director
- Robert B. ShapiroDirector
- Jeffrey B. KindlerDirector
- Cesar L. AlvarezDirector
- Nir NimrodiExecutive Officer
- Offering amount
- $450K
- Amount sold
- $450K
- First sale
- Feb 2015
- Incorporated
- Corporation, Virginia
- Federal exemptions
- 06b
▶$10.2MraisedMar 2015 · 78 investors · BiotechnologyRule 506(b)
▶$10.2MraisedMar 2015 · 78 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Robert F. Walsh, IIIExecutive Officer
- Robert B. ShapiroDirector
- Suma M. KrishnanExecutive Officer
- Jeffrey T. PerezExecutive Officer
- Gregory I. FrostExecutive Officer
- Donald P. LehrExecutive Officer
- Krish S. KrishnanExecutive Officer
- Thomas D. ReedExecutive Officer
- Jeffrey B. KindlerDirector
- Thomas R. KasserExecutive Officer
- Randal J. KirkExecutive Officer, Director
- James S. TurleyDirector
- Dean J. MitchellDirector
- Rick L. SterlingExecutive Officer
- Darryl WebsterExecutive Officer
- Nir NimrodiExecutive Officer
- Larry D. HornerDirector
- Steven FrankDirector
- Cesar L. AlvarezDirector
- Offering amount
- $10.2M
- Amount sold
- $10.2M
- First sale
- Feb 2015
- Incorporated
- Corporation, Virginia
- Federal exemptions
- 06b
▶$57.5MraisedJan 2015 · 1 investors · BiotechnologyRule 506(b)
▶$57.5MraisedJan 2015 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Thomas R. KasserExecutive Officer
- Dean J. MitchellDirector
- Thomas D. ReedExecutive Officer
- Robert B. ShapiroDirector
- Cesar L. AlvarezDirector
- Suma M. KrishnanExecutive Officer
- Jeffrey B. KindlerDirector
- Donald P. LehrExecutive Officer
- Steven FrankDirector
- James S. TurleyDirector
- Larry D. HornerDirector
- Robert F. Walsh, IIIExecutive Officer
- Rick L. SterlingExecutive Officer
- Randal J. KirkExecutive Officer, Director
- Krish S. KrishnanExecutive Officer
- Darryl WebsterExecutive Officer
- Gregory I. FrostExecutive Officer
- Nir NimrodiExecutive Officer
- Offering amount
- $57.5M
- Amount sold
- $57.5M
- First sale
- Jan 2015
- Incorporated
- Corporation, Virginia
- Federal exemptions
- 06b
▶$28.6MraisedAug 2014 · 5 investors · BiotechnologyRule 506(b)
▶$28.6MraisedAug 2014 · 5 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Thomas R. KasserExecutive Officer
- Gregory I. FrostExecutive Officer
- Robert B. ShapiroDirector
- Randal J. KirkExecutive Officer, Director
- Dean J. MitchellDirector
- Jeffrey B. KindlerDirector
- Steven FrankDirector
- Thomas D. ReedExecutive Officer
- Donald P. LehrExecutive Officer
- Darryl WebsterExecutive Officer
- Larry D. HornerDirector
- Rick L. SterlingExecutive Officer
- Krish S. KrishnanExecutive Officer
- Robert F. Walsh, IIIExecutive Officer
- Suma M. KrishnanExecutive Officer
- Nir NimrodiExecutive Officer
- Cesar L. AlvarezDirector
- James S. TurleyDirector
- Offering amount
- $28.6M
- Amount sold
- $28.6M
- First sale
- Aug 2014
- Incorporated
- Corporation, Virginia
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 4
by search overlapBiogen Idec113 shared keywordsBiogen is a biotechnology company founded in 1978 that focuses on breakthroughs in biology. The company serves patients through research and development in the life sciences industry.
PepGen72 shared keywordsPepGen develops disease-modifying therapeutics aimed at the underlying causes of serious genetic neuromuscular and neurological diseases. The company is building a pipeline of oligonucleotide-based treatments for these conditions.
Robinhood63 shared keywordsRobinhood is a financial trading platform that enables users to manage portfolios across stocks, ETFs, cryptocurrencies, options, futures, and prediction markets. The platform serves retail investors with low barriers to entry, offering portfolio management services and market insights.
Seeking Alpha59 shared keywordsSeeking Alpha is a financial research platform offering stock analysis, market news, investment ideas, and quantitative ratings across asset classes, drawing on a large community of contributing analysts. It serves individual and professional investors seeking research and data-driven insight on stocks and markets.
Companies competing with Precigen for the same Google search keywords, organic and paid, via search-intersection analysis.
Acquisitions · 1
Early investors' stakes continue via these dealsOxitec
Flyttr operates a biosecurity platform that develops and deploys countermeasures against pest threats, combining autonomous pest monitoring systems, AI-powered decision-support, and biological interventions such as engineered Aedes aegypti and Wolbachia. It serves national governments, agricultural authorities, industry partners and field operators across public health, agriculture, and livestock domains.
In the news
Precigen (PGEN) Could Be 50% Undervalued On Strong Earnings Turnaround - Simply Wall St Newssimplywall.st · Aug 2026Frequently asked questions
- What does Precigen do?
- Precigen is a biopharmaceutical company developing gene and cell therapies, including PAPZIMEOS (zopapogene imadenovec-drba), an FDA-approved immunotherapy for adults with recurrent respiratory papillomatosis. The company focuses on immuno-oncology and immunotherapy treatments delivered via subcutaneous injection.
- Who founded Precigen?
- Precigen was founded by Thomas D. Reed.
- Who are Precigen's investors?
- Precigen's investors include Third Point Ventures, Third Security, LLC.
- How much funding has Precigen raised?
- Precigen has disclosed $245.6M raised across 10 rounds.
- Where is Precigen headquartered?
- Precigen is headquartered in Germantown, US.